Novartis’ Haseeb Ahmad is set to become president of the The Association of the British Pharmaceutical Industry (ABPI), where he will take over the role vacated by Erik Nordkamp and lead on overseeing both the ABPI, the ABPI Board and the ABPI’s Code of Practice.
In his new role he will take advantage of the opportunities presented by science, technology and data to help get new medicines to patients faster, whilst promoting innovation and collaboration with the NHS and government, which will not only improve outcomes for patients but also boost the UK economy.
Haseeb said of his appointment: “We are in a golden era of medicines discovery, where innovative science is converging with a data and digital revolution. These forces are coming together to treat and potentially cure diseases on a scale the likes of which we’ve not seen before.”
Haseeb is Novartis UK country president and managing director UK & Ireland of Novartis, and has held senior in-country appointments, including managing director for MSD in Greece during the economic crisis, and above-country roles in Strategy, Operations, Sales and Marketing.
He continued, “The pharmaceutical industry, Government and the NHS must work together to ensure that patients can access innovative therapies and that we deliver the kind of healthcare that all of us in the UK deserve.”
Haseeb has previously led the American Chamber of Commerce Pharma Group, is a member of the ABPI board and Novartis European Executive Committee. He is recognised as a leader who enables winning performance by working collaboratively with customers and has a passion for innovation in healthcare delivery.
By Anna Smith
Source: Pharma Times
Since it launched in 2018, Accent Therapeutics has busied itself discovering new targets for cancer drugs in the space of RNA-modifying proteins. But the time for lying low is over—just […]
Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was […]
Johnson and Johnson’s experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency’s human medicines committee (CHMP) at its May meeting. […]